Last year, Sepracor, the maker of sleeping pill Lunesta, announced it would reduce its sales and marketing expenses by $90-100 million in 2008, "including an anticipated reduction of approximately 300 ...

Sepracor will eliminate 300 sales force positions as part of a cost cutting plan to reduce expenses by $90 million-$100 million for 2008. “We have examined our sales organization in depth,” Adrian ...

Sepracor will launch a $60 million dollar marketing and advertising campaign for its new sleeping pill Lunesta in the coming week. Ads for the drug will tout Lunesta’s advantages, Sepracor chief ...

Two separate moves, by Sanofi-Aventis and Sepracor, illustrate the power that drug companies can have over the taxes of towns they base their headquarters in. Sanofi backed out of a deal in ...

Marlborough pharmaceutical company Sepracor Inc. says a phase III study of its nasal aerosol hay fever treatment had positive results. The company said the treatment, OMNARIS HFA, reduced nasal ...

Mark Iwicki, the new president and COO at Sepracor, says the company, under new Japanese ownership, will focus on niche market drugs. PHOTO/COURTESY The $2.6 billion move for Dainippon Sumitomo Pharma ...

Overall planned operating expense reduction of approximately $210.0 million, of which approximately $20.0 million of cost savings was realized in the fourth quarter of 2008 and approximately $190.0 ...

Spotted a moth lately? Fewer and fewer people have, and for good reason. Sepracor has started to cut back its consumer ads, making that familiar Lunesta moth something of an endangered critter. At ...

Agreements cover a company acquisition for $50 million and rights to enhance brand management within its respiratory disease portfolio. Sepracor reports multiple deals with the Arrow Group, including ...

MARLBOROUGH, Mass.--(BUSINESS WIRE)--Sepracor Inc. and Dainippon Sumitomo Pharma Co., Ltd. (DSP) today announce the resignation of Adrian Adams as President and Chief Executive Officer and Director of ...

LOS ANGELES (MarketWatch) -- Shares of Sepracor jumped more than 8 percent Thursday on reports that the drugmaker could be the target of a buyout and is evaluating strategic options. Sepracor SEPR ...

Sepracor Inc. and Dainippon Sumitomo Pharma Co., Ltd. (DSP) today announce the resignation of Adrian Adams as President and Chief Executive Officer and Director of Sepracor and as Executive Officer of ...